Petrozziello Elisabetta, Sturmheit Tabea, Mondino Anna
Division of Immunology, Transplantation & Infectious Diseases, San Raffaele Scientific Institute, Via Olgettina, 58, 20132 Milan, Italy.
Vita-Salute San Raffaele University, San Raffaele Scientific Institute Milan, Italy.
Immunotherapy. 2015;7(5):573-84. doi: 10.2217/imt.15.19.
Adoptive immunotherapy with tumor-reactive autologous T cells, either expanded from tumor specimens or genetically engineered to express tumor-reactive T-cell receptors and chimeric antigen receptors, is holding promising results in clinical trials. Several critical issues have been identified and results underline the possibility to exploit cytokines to further ameliorate the efficacy of current treatment protocols, also encompassing adoptive T-cell therapy. Here we review latest developments on the use of cytokines to better direct the nature of the T-cell infusion product, T-cell function and persistence in vivo, as well as to modulate the tumor microenvironment.
采用肿瘤反应性自体T细胞进行过继性免疫治疗，这些T细胞可从肿瘤标本中扩增，或经过基因工程改造以表达肿瘤反应性T细胞受体和嵌合抗原受体，目前在临床试验中取得了令人鼓舞的结果。已经发现了几个关键问题，结果表明利用细胞因子进一步改善当前治疗方案（包括过继性T细胞疗法）疗效的可能性。在此，我们综述了细胞因子在更好地指导T细胞输注产物的性质、T细胞在体内的功能和持久性以及调节肿瘤微环境方面的最新进展。
